Allergan issues guidance for Q4, sees EPS of $0.97-0.99




Allergan, Inc. (NYSE:AGN). Last Market Price: 84.05, Change: -2.91, % Change: (-3.35%). Shares trade in the range of 82.80 – 86.34 dollars. It has a market capitalization of 25.64B dollars, making it a Large Cap Stock and has 305.06M outstanding shares. The company has a beta of 0.87, indicating, the stock to be less volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.06. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 92%. The company has a 52 week Price range (low – high) of $ 66.11 – 89.25. Average volumes of shares traded daily are 2,170,000. Volume traded in the last session was at 2,510,000, 1.16 times the average volume.

  • Reports Q3 (Sep) EPS of $0.92 , better than the estimates
  • Revenues rose 9.9% year/year to $1.33 billion
  • Company issues guidance for Q4, sees EPS of $0.97-0.99
  • States: We are very pleased with the progress of the launch of BOTOX for chronic migraine in the United States and with the opportunity represented by the recent approvals of BOTOX for urinary incontinence in adults with neurologic conditions.

For Q2 (Jun ’11), It had a Net profit margin of 17.54%, an Operating margin of 25.63%. Other Key stats and ratios are : Return on average assets of 12.27%, Return on average equity of 20.13%. The organization has an employee strength of 9,000

Consensus Recommendation is a Outperform.


Estimate for sales for the Quarter Ending Dec-11 show a mean of 1,412.68 million dollars, an estimate high of 1,446.60 million dollars and an estimate low of 1,349.60 million dollars. A year ago the figures stood at 1,365.83 million dollars.

Estimate for sales for the Quarter Ending Mar-12 show a mean of 1,380.68 million dollars, an estimate high of 1,421.60 million dollars and an estimate low of 1,335.00 million dollars. A year ago the figures stood at 1,303.71 million dollars.

Estimate for EPS for the Quarter Ending Dec-11 show a mean of 1.01 dollars, an estimate high of 1.05 dollars and an estimate low of 0.98 dollars. A year ago the figures stood at 1.01 dollars.

Estimate for EPS for the Quarter Ending Mar-12 show a mean of 0.91 dollars, an estimate high of 0.95 dollars and an estimate low of 0.88 dollars. A year ago the figures stood at 0.87 dollars.

Sales for Quarter Ending Jun-11 was estimated at 1,339.08 million dollars, however the actual sales figure stood at 1,417.20 million dollars, 78.12 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 1,215.64 million dollars, however the actual sales figure stood at 1,271.20 million dollars, 55.56 million dollars more than estimates.


edliston
Post Written By: Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.


Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...